who should not take glp 1 receptor agonists GLP-1 Agonists: Mascots & Mnemonics Glucagon-Like Peptide-1 Receptor Agonists in
Description
GLP-1 has opposing effects on hepatic lipid accumulation and plasma lipid levels, which has recently broadened its clinical use in pharmacological therapy of metabolic syndrome and steatohepatitis 8,9
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K
The transition from Phase 2 to Phase 3 also involved refinement of the dose-escalation schedule
MASLD consists of different conditions, including isolated liver steatosis (metabolic dysfunction-associated steatotic liver, MASL), metabolic dysfunction associated steatohepatitis (MASH), as well as fibrosis and cirrhosis
, decreased compared to placebo
